- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.10. | PESG Research: PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update | 166 | Business Wire | Nuvectis Pharma (NASDAQ: NVCT) continues to make strides in precision oncology, gaining momentum following presentations last week at the AACR-NCI-EORTC Symposium where its drug candidate NXP900... ► Artikel lesen | |
| 16.09. | PESG Research: PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch | 424 | Business Wire | With its focus on targeting well-defined subgroups by inhibiting SRC/YES1 kinases in Non Small-Cell Lung Cancer patients resistant to EGFR and ALK targeted therapies, Nuvectis Pharma's NXP900 could... ► Artikel lesen | |
| 05.09. | Nuvectis Pharma, Inc.: Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference | 1 | GlobeNewswire (USA) | ||
| 30.08. | Nuvectis' NXP800 gains FDA ODD for cancer treatment | 1 | Pharmaceutical Technology | ||
| 29.08. | Nuvectis's NXP800 Granted FDA Orphan Drug Designation For ARID1a-Deficient Ovarian Cancers | 1 | RTTNews | ||
| 29.08. | Nuvectis gains on FDA's orphan drug designation for cancer therapy | 1 | Seeking Alpha | ||
| 29.08. | Nuvectis Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.08. | Nuvectis Pharma receives FDA orphan drug status for cancer treatment | 1 | Investing.com | ||
| 29.08. | Nuvectis Pharma, Inc.: Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers | 75 | GlobeNewswire (Europe) | FORT LEE, N.J., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative... ► Artikel lesen | |
| 06.08. | Nuvectis Pharma reports Q2 results | 1 | Seeking Alpha | ||
| 06.08. | Nuvectis Pharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.06. | Nuvectis Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.05. | Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference | 1 | GlobeNewswire (USA) | ||
| 07.05. | Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights | 135 | GlobeNewswire (Europe) | Encouraging preliminary data announced from the NXP800 Phase 1b study in platinum resistant, ARID1a-mutated ovarian cancer, a program granted Fast Track Designation by the US FDAData presented at... ► Artikel lesen | |
| 08.04. | Nuvectis Pharma, Inc.: Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines | 175 | GlobeNewswire (Europe) | Highly Synergistic Antiproliferative Activity in EGFR-resistant Cells in Combination with Osimertinib, the Active Ingredient in TagrissoTM Single Agent Antiproliferative Activity in Cells Resistant... ► Artikel lesen | |
| 14.03. | Nuvectis Pharma, Inc.: Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer | 159 | GlobeNewswire (Europe) | 33% Response Rate and 100% Disease Control Rate Observed in Patients Evaluated for EfficacyComplete Response of Non-Target Tumor Also Observed Platinum-Resistant Ovarian Cancer is a Devastating Serious... ► Artikel lesen | |
| 05.03. | Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights | 114 | GlobeNewswire (Europe) | NXP800 preliminary data update expected this month from the Phase 1b study in platinum resistant, ARID1a mutated ovarian cancer, a program that has been granted Fast Track Designation by the FDANXP800... ► Artikel lesen | |
| 08.11.23 | Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights | 231 | GlobeNewswire (Europe) | Phase 1b Study of NXP800 in Patients with Platinum Resistant, ARID1a-Mutated Ovarian Carcinoma is Ongoing Initiated the Phase 1a Dose Escalation Study of NXP900 in Patients with Advanced Solid TumorsNXP800... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,300 | +44,44 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,448 | +17,59 % | Defence Therapeutics Inc.: Defence Therapeutics Completes 1st Tranche of Financing | Vancouver, British Columbia--(Newsfile Corp. - October 30, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| GINKGO BIOWORKS | 6,950 | -2,80 % | Lesaffre strengthens its Research, Development & Innovation (RD&I) with the acquisition of Altar, a company owned by Ginkgo Bioworks | MARCQ-EN-BARŒUL, France, Oct. 7, 2024 /PRNewswire/ -- Lesaffre, a key global player in the field of fermentation and microorganisms, announces the acquisition of Altar, a French start-up... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,505 | +1,09 % | Peering Into Recursion Pharmaceuticals' Recent Short Interest | ||
| BEAM THERAPEUTICS | 24,065 | +5,55 % | Beam Therapeutics' Earnings: A Preview | ||
| ONCOLYTICS BIOTECH | 1,080 | 0,00 % | Oncolytics Biotech Inc.: Oncolytics Biotech Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study | Overall survival (OS) results from BRACELET-1 corroborate results of previous randomized IND-213 breast cancer study
Together, these two studies support the compelling potential of pelareorep-based... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 18,020 | +1,64 % | Arcturus Gears Up to Report Q3 Earnings: Here's What to Expect | ||
| ASSERTIO | 1,050 | +0,96 % | Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | LAKE FOREST, Ill., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 7,080 | -2,48 % | SIGA Technologies Inc.: SIGA to Host Business Update Call on November 7 Following Release of Third-Quarter 2024 Financial Results | ||
| ADMA BIOLOGICS | 19,290 | +0,23 % | ADMA Biologics, Inc. (NASDAQ:ADMA) Holdings Increased by Roman Butler Fullerton & Co. | ||
| VIR BIOTECHNOLOGY | 9,450 | +3,17 % | Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen | |
| MERRIMACK PHARMACEUTICALS | 15,130 | 0,00 % | Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") announced that the stockholders at a Special Meeting held today overwhelmingly approved... ► Artikel lesen | |
| VERVE THERAPEUTICS | 5,960 | +2,76 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 15,900 | -2,45 % | Travere Therapeutics, Inc.: Travere Therapeutics Reports Third Quarter 2024 Financial Results | FILSPARI® (sparsentan) received full FDA approval as the only non-immunosuppressive treatment that significantly slows kidney function decline in IgAN Type C meeting scheduled with FDA to discuss... ► Artikel lesen | |
| ARVINAS | 27,410 | +4,26 % | Arvinas Inc.: Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update | - On track to report topline data from Phase 3 VERITAC-2 trial in 4Q24 or 1Q25 - - Initial clinical data from Phase 1/2 TACTIVE-U sub-study of abemaciclib in combination with vepdegestrant to be presented... ► Artikel lesen |
Das Unternehmen NUVECTIS PHARMA INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,150 (-2,25 %) liegt der Kurs bei 6,510 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NUVECTIS PHARMA INC finden Sie auf Wallstreet Online.
